­
­
­
­

Inventi Impact: Oncology

Articles

  • Inventi:hoc/33075/20
    Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
    Research 2021 : January - March
    Bi-Cheng Wang, Bo-Ya Xiao, Peng-Cheng Li, Bo-Hua Kuang, Wang-Bing Chen, Pin-Dong Li, Guo-He Lin, Quentin Liu

    Background. The prognosis of patients with extensive-stage small cell lung cancer (SCLC) is poor. Adding an immune checkpoint\ninhibitor (ICI) to chemotherapy may exert a synergistic effect and improve survival outcomes. However, for treatment-naive\nextensive-stage SCLC patients, the efficacy of immunotherapy in combination with cytotoxic chemotherapy remains controversial.\nObjective. To evaluate the benefits and risks of the combination of immunotherapy and chemotherapy and to assess the\ncomparative effectiveness of different first-line treatment strategies for extensive-stage SCLC. Methods. PubMed, Web of Science,\nEMBASE, and Cochrane Library were searched for randomized clinical trials studying different immunotherapeutics for patients\nwith previously untreated extensive-stage SCLC up to Feb 16, 2020. The primary outcomes were overall survival (OS) and\nprogression-free survival (PFS), and the secondary outcomes were objective response rate (ORR), disease control rate (DCR), and\nadverse events.....................

    How to Cite this Article
    Attribution/ CC Compliant Citation: Wang, Bi-Cheng, et al.\n\"Efficacy and Safety of First-Line Immunotherapy in\nCombination with Chemotherapy for Patients with\nExtensive-Stage Small Cell Lung Cancer: A Systematic Review\nand Network Meta-Analysis.\" Journal of oncology 2020\n(2020).\nhttps://doi.org/10.1155/2020/2368164\nhttp://creativecommons.org/licenses/by/4.0/\nSome formatting elements, header, footer, logos, dates and\npagination were modified while adapting this article.
    Download Full Text